Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota.
The new age of nanotechnology has signaled a stream of entrepreneurial possibilities in various areas, form industry to medicine. Drug delivery has benefited the most by introducing nanostructured systems in the transport and controlled release of therapeutic molecules at targeted sites associated with a particular disease. As many nanosized particles reach the gastrointestinal tract by various means, their interactions with the molecular components of this highly active niche are intensively investigated. The well-characterized antimicrobial activities of numerous nanoparticles are currently being considered as a reliable and efficient alternative to the eminent world crisis in antimicrobial drug discovery. The interactions of nanosystems present in the gastrointestinal route with host microbiota is unavoidable; hence, a major research initiative is needed to explore the mechanisms and effects of these nanomaterials on microbiota and the impact that microbiota may have in the outcome of therapies entailing drug delivery nanosystems through the gastrointestinal route. These coordinated studies will provide novel techniques to replace or act synergistically with current technologies and help develop new treatments for major diseases via the discovery of unique antimicrobial molecules.
Aberdeen, Scotland AB15 5LZ, UK. mike_kar@hotmail.com.
Michail
M
Karavolos
Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, Bucharest 77206, Romania. alina_m_h@yahoo.com.|Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, Bucharest 011061, Romania. alina_m_h@yahoo.com.
Alina
A
Holban
antimicrobial; gastrointestinal delivery; infection; microbiota; nanotechnology; pathogen
Int J Food Microbiol. 2010 Nov 15;144(1):51-63
20951455
Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):44-54
27158095
Biomaterials. 2009 Oct;30(29):5675-81
19631376
Nature. 2010 Mar 4;464(7285):59-65
20203603
Nature. 2006 Dec 21;444(7122):1022-3
17183309
Molecules. 2014 Aug 20;19(8):12710-26
25140449
Int J Biomed Nanosci Nanotechnol. 2013;3(1-2):
24228068
Part Fibre Toxicol. 2013 Apr 15;10:15
23587290
Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18
19782542
J Cell Physiol. 2016 Aug;231(8):1688-94
26660761
Chem Soc Rev. 2011 Mar;40(3):1647-71
21082078
BJOG. 2017 Jan;124(1):61-69
27396541
Nature. 2012 Jun 13;486(7402):207-14
22699609
N Engl J Med. 2014 Mar 27;370(13):1198-208
24670166
Nat Rev Microbiol. 2008 Oct;6(10):776-88
18794915
ACS Nano. 2010 Mar 23;4(3):1481-92
20175510
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006475
17943912
Int J Mol Sci. 2016 Apr 06;17(4):509
27058534
Infect Dis (Lond). 2016 Aug;48(8):587-92
27194400
Infect Immun. 2016 Aug 19;84(9):2639-52
27382022
Clin Microbiol Infect. 2016 Jul;22(7):594-9
27179648
J Agric Food Chem. 2010 Mar 24;58(6):3689-93
20187606
Nature. 2012 Jun 13;486(7402):215-21
22699610
Curr Opin Obstet Gynecol. 2016 Oct;28(5):407-12
27379439
Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):508-16
27329806
Intest Res. 2016 Apr;14(2):127-38
27175113
Nanotoxicology. 2016;10(5):513-20
26525505
Toxicology. 2012 Jan 27;291(1-3):10-7
22120540
Part Fibre Toxicol. 2013 Mar 26;10:9
23531334
J Food Sci. 2011 Mar;76(2):N16-24
21535781
Nature. 2016 Jul 06;535(7610):65-74
27383981
Eur J Pharm Sci. 2010 Jan 31;39(1-3):82-9
19903527
Curr Pharm Biotechnol. 2015;16(2):87-93
25420724
Nat Nanotechnol. 2009 Jul;4(7):411-4
19581891
Antimicrob Agents Chemother. 2004 Apr;48(4):1222-8
15047523
Int J Pharm. 2004 Dec 9;287(1-2):163-73
15541923
Adv Drug Deliv Rev. 2012 May 1;64(6):557-70
22212900
J Infect Dis. 2016 Jul 1;214(1):130-9
26917573
Carbohydr Polym. 2015 Oct 5;130:429-39
26076644
ACS Nano. 2013 Jan 22;7(1):214-28
23259666
Colloids Surf B Biointerfaces. 2011 Nov 1;88(1):39-44
21752610
Colloids Surf B Biointerfaces. 2011 Feb 1;82(2):414-21
20951006
Risk Anal. 2010 Nov;30(11):1634-44
20626687
Int J Pharm. 2016 Aug 30;510(2):409-18
26945736
Int J Nanomedicine. 2007;2(2):129-41
17722542
Infect Dis Ther. 2016 Sep;5(3):231-51
27370914
Appl Biochem Biotechnol. 2014 Apr;172(8):3810-26
24574250
BMJ Open Gastroenterol. 2016 May 09;3(1):e000087
27239328
Curr Drug Metab. 2015;16(4):255-71
26264194
Sci Rep. 2014 Feb 19;4:4134
24549289
Cell. 2006 Feb 24;124(4):837-48
16497592
Trends Microbiol. 2016 Sep;24(9):750-765
27320172
Small. 2013 Aug 26;9(16):2735-46
23463684
Acta Orthop. 2009 Oct;80(5):514-9
19916681
Biomaterials. 2009 Sep;30(27):4738-42
19500839
Crit Rev Toxicol. 2006 Mar;36(3):189-217
16686422
Nanomedicine. 2007 Jun;3(2):161-7
17468055
Physiol Rev. 2010 Jul;90(3):859-904
20664075
J Control Release. 2010 Mar 3;142(2):149-59
19850093
J Pharm Pharmacol. 1990 Dec;42(12):821-6
1983142
Sci Total Environ. 2013 Mar 1;447:90-8
23376520
Int J Pharm. 2015 Oct 15;494(1):49-65
26260231
J Antibiot (Tokyo). 2011 Sep;64(9):625-34
21811264
Science. 2005 Jun 10;308(5728):1635-8
15831718
Int J Pharm. 2006 Apr 7;312(1-2):166-73
16497452
J Endod. 2010 Feb;36(2):322-8
20113801